Carla van Herpen has been appointed Professor of Rare Cancers at Radboud University/Radboud university medical center from 1 January 2018. Van Herpen is the first Professor of Rare Cancers in the Netherlands.
Carla van Herpen (theme: Rare Cancers) will work to improve survival rate and quality of life for patients with rare cancers, paying special attention to salivary gland cancer and head and neck cancer. Rare cancers are characterised by poorer survival rates than more frequently observed cancers because there is often a delay in making the correct diagnosis, fewer adequate therapies are available, and fewer clinical trials are being set up for them.
Carla van Herpen earned her doctor’s qualification from Radboud University in 1989. She then completed the internal medicine programme at Canisius-Wilhelmina Hospital and Radboud university medical center, and did her follow-up training to become an internist-oncologist at Radboud university medical center. She has been a staff member in the Medical Oncology Department at Radboud university medical center since 1997.
In 2004, she earned her PhD from Radboud University with her dissertation: ‘Intratumoral administration of interleukin-12 in head and neck cancer’. In 2015-2016, she completed an executive course, Managing Health Care Delivery, at Harvard Business School in Boston, Massachusetts (USA).
Medical Oncology clinic
Van Herpen was head of the Medical Oncology clinic from 2005 to 2009 and has subsequently focused more on pioneering research into, among other things, new drugs (phase I–early phase II research). She has been the rare cancers theme leader since 2015, and the coordinator of the molecular tumour board at Radboud university medical center since 2016.
Dr van Herpen also holds a number of national positions. She is a board member for the Nederlandse Vereniging voor Medische Oncologie (Dutch Society for Medical Oncology, NVMO), sits on the executive board of Stichting Oncologische Samenwerking (Oncological Collaboration Foundation, SONCOS) and is co-chair of the regional practicability work group of the Dutch Clinical Research Foundation (DCRF).
Related news items
Guiding the surgeon real-time tumor visualization during surgery26 February 2020
Incomplete excision of tumor tissue negatively affects the prognosis of the patient. RIHS researcher Mark Rijpkema and colleagues are working on the development of new dual-labeled tracers and currently are implementing this into the clinic.read more
Cognitive behavioral therapy reduces severe fatigue in patients with advanced cancer during treatment28 January 2020
In Annals of Oncology, RIHS researchers Hanneke Poort, Marlies Peters, Winette van der Graaf, Ria Nijhuis-van der Sanden and colleagues showed significant effects of cognitive behavioral therapy on fatigue in patients with advanced cancer during treatment with palliative intent.read more
Drug-induced interstitial lung disease in advanced breast cancer patients receiving everolimus22 August 2019
In Targeted Oncology, Annelieke Willemsen, Carla van Herpen and colleagues, showed that pulmonary function test with diffusion capacity of the lungs for carbon monoxide and serum biomarkers can be of aid to differentiate everolimus-related interstitial lung disease from other respiratory problems.read more
Sarah Verhoeff wins audience award Radboud Talks Jury chose neuroscientist as overall winner26 March 2019
The winner of the fifth edition of scientific pitch competition Radboud Talks is Suhas Vijayakumar, PhD candidate at the Faculty of Social Sciences and the Donders Institute. Research physician Sarah Verhoeff, Radboud Institute for Health Sciences, won the audience award.read more
Publication on Salivary duct cancer in the International Journal of Cancer28 March 2018
Eline Boon and Carla van Herpen described 177 patients with Salivary duct cancer (Rare cancers) with detailed information regarding treatment, outcomes and prognostic factors.read more